Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | ATM | Q13315 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9383601 | 0.87 | CCNA2 (0.35) | CYP1A2CCNA2CDK2CCNA1MAPT | |
| SCHEMBL5762695 | 0.80 | ALDH1A1 (0.33) | CYP1A2MAPTALDH1A1 | |
| SCHEMBL16828162 | 0.80 | CCNA2 (0.50) | CCNA2CDK2CCNA1ALDH1A1ATM | |
| Hydrochloric Acid SCHEMBL16828222 | 0.78 | CCNA2 (0.48) | CCNA2CDK2CCNA1ALDH1A1ATM | |
| SCHEMBL3674088 | 0.78 | PKM (0.37) | CCNA2CDK2CCNA1MAPTTSHR | |
| SCHEMBL9124627 | 0.76 | KDM4E (0.33) | MAPTALDH1A1MEN1KMT2AHTT | |
| SCHEMBL6639436 | 0.76 | CYP1A2 (0.47) | CYP1A2CCNA2CDK2CCNA1MAPT | |
| SCHEMBL5765140 | 0.75 | TLR7 (0.36) | TSHR | |
| SCHEMBL10604745 | 0.75 | CCNA2 (0.34) | CYP1A2CCNA2CDK2CCNA1 | |
| SCHEMBL4271009 | 0.74 | CYP1A2 (0.40) | CYP1A2MAPTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415811-B2 | 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-C]pyrrole]-2,3'-dione compounds as therapeutic agents activating TP53 | ADAMED PHARMA S.A. (PL) | 2025-09-16 | — | — | US | disclosed |
| CN-111566110-B | 1,2,3',5' -tetrahydro-2 ' H-spiro [ indole-3, 1' -pyrrolo [3,4-C ] pyrrole ] -2,3' -dione compounds as therapeutic agents for activating TP53 | 阿达梅德制药公司 | 2023-04-25 | — | — | CN | disclosed |
| EP-3740492-B1 | 1,2,3',5'-TETRAHYDRO-2'H-SPIRO[INDOLE-3,1'-PYRROLO[3,4-C]PYRROLE]-2,3'-DIONE COMPOUNDS AS THERAPEUTIC AGENTS ACTIVATING TP53 | ADAMED PHARMA S A (PL) | 2022-03-02 | — | — | EP | disclosed |
| EP-3740492-A1 | 1,2,3',5'-TETRAHYDRO-2'H-SPIRO[INDOLE-3,1'-PYRROLO[3,4-C]PYRROLE]-2,3'-DIONE COMPOUNDS AS THERAPEUTIC AGENTS ACTIVATING TP53 | Adamed Pharma S.A. (PL) | 2020-11-25 | — | — | EP | disclosed |
| US-20200354372-A1 | 1,2,3',5'-TETRAHYDRO-2'H-SPIRO[INDOLE-3,1'-PYRROLO[3,4-C]PYRROLE]-2,3'-DIONE COMPOUNDS AS THERAPEUTIC AGENTS ACTIVATING TP53 | ADAMED PHARMA, S.A. (PL) | 2020-11-12 | — | — | US | disclosed |
| US-20200354372-A1 | 1,2,3',5'-TETRAHYDRO-2'H-SPIRO[INDOLE-3,1'-PYRROLO[3,4-C]PYRROLE]-2,3'-DIONE COMPOUNDS AS THERAPEUTIC AGENTS ACTIVATING TP53 | ADAMED PHARMA, S.A. (PL) | 2020-11-12 | — | — | US | disclosed |
| CN-111566110-A | 1,2,3',5' -tetrahydro-2 ' H-spiro [ indole-3, 1' -pyrrolo [3,4-C ] pyrrole ] -2,3' -dione compounds as therapeutic agents for activating TP53 | 阿达梅德制药公司 | 2020-08-21 | — | — | CN | disclosed |
| WO-2019141549-A9 | 1,2,3',5'-TETRAHYDRO-2'H-SPIRO[INDOLE-3,1'-PYRROLO[3,4-C]PYRROLE]-2,3'-DIONE COMPOUNDS AS THERAPEUTIC AGENTS ACTIVATING TP53 | ADAMED PHARMA S.A. (PL) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019141549-A9 | 1,2,3',5'-TETRAHYDRO-2'H-SPIRO[INDOLE-3,1'-PYRROLO[3,4-C]PYRROLE]-2,3'-DIONE COMPOUNDS AS THERAPEUTIC AGENTS ACTIVATING TP53 | ADAMED PHARMA S.A. (PL) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019141549-A1 | 1,2,3',5'-TETRAHYDRO-2'H-SPIRO[INDOLE-3,1'-PYRROLO[3,4-C]PYRROLE]-2,3'-DIONE COMPOUNDS AS THERAPEUTIC AGENTS ACTIVATING TP53 | ADAMED PHARMA S.A. (PL) | 2019-07-25 | — | — | WO | disclosed |
| US-7407649-B2 | Compounds having a benzene ring substituted with 1 or 2 trialkylsilyl(alkyl) groups and at least 2 additional aryl or heteroaryl rings: 5-[2-methyl-5-(trimethylsilyl)phenoxy]-N-(2,6-dimethoxyphenyl)furan-2-carboxamide; Gonadotropin-Releasing Hormone antagonists; anticancer agents | PARADIGM THERAPEUTICS LTD (GB) | 2008-08-05 | — | — | US | disclosed |
| US-20070110708-A1 | Silicon compounds and their use | PARADIGM THERAPEUTICS LTD (GB) | 2007-05-17 | — | — | US | disclosed |
| US-20070110708-A1 | Silicon compounds and their use | PARADIGM THERAPEUTICS LTD (GB) | 2007-05-17 | — | — | US | disclosed |
| US-20070111967-A1 | Organosilicon compounds and their use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-17 | — | — | US | disclosed |
| US-20070111967-A1 | Organosilicon compounds and their use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-17 | — | — | US | disclosed |
| EP-1334972-B1 | Non-peptide compounds affecting the action of gonadotropin-releasing hormone (GnRH) | PFIZER (US) | 2006-04-19 | — | — | EP | disclosed |
| US-6833372-B2 | A hormone inhibitors of gonadotropin releasing hormone, an antigonadotropins, new drug compound contains a furanyl 2-carboxylic acid -(2,4-dimethoxy-pyrimidin-5-yl)-amide groups | PFIZER, INC. | 2004-12-21 | — | — | US | disclosed |
| US-20040053951-A1 | Non-peptide GnRH agents, pharmaceutical compositions, and methods for their use | PFIZER INC. | 2004-03-18 | — | — | US | disclosed |
| WO-2003068769-A1 | NON-PEPTIDE COMPOUNDS AFFECTING THE ACTION OF GONADOTROPIN-RELEASING HORMONE (GNRH) | PFIZER INC. (US) | 2003-08-21 | — | — | WO | disclosed |
| EP-1334972-A1 | Non-peptide compounds affecting the action of gonadotropin-releasing hormone (GnRH) | PFIZER INC. (US) | 2003-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070110708-A1 | Silicon compounds and their use | SOST, SMAD3, SMAD2 | CYP1A2 482/4885CCNA2 810/4885CDK2 1283/4885 |
| US-12415811-B2 | 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-C]pyrrole]-2,3'-dione compounds as therapeutic agents activating TP53 | TP53, IDO1, TP53BP1 | CYP1A2 730/4885CCNA2 27/4885CDK2 89/4885 |
| US-20070111967-A1 | Organosilicon compounds and their use | CYP2B6, UGT1A6, CYP2D6 | CYP1A2 6/4885CCNA2 763/4885CDK2 795/4885 |
| US-20040053951-A1 | Non-peptide GnRH agents, pharmaceutical compositions, and methods for their use | GNRHR, LHCGR, FSHR | CYP1A2 4818/4885CCNA2 1676/4885CDK2 2937/4885 |
| US-20200354372-A1 | 1,2,3',5'-TETRAHYDRO-2'H-SPIRO[INDOLE-3,1'-PYRROLO[3,4-C]PYRROLE]-2,3'-DIONE COMPOUNDS AS THERAPEUTIC AGENTS ACTIVATING TP53 | TP53, IDO1, TP53BP1 | CYP1A2 730/4885CCNA2 27/4885CDK2 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.